MapLight Therapeutics
Last verified 2026-05-26. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $400.0Mattributed |
|---|---|
| Latest round | series-d+, $372.5M, 2025-07-01attributed |
| Founded | 2018 |
| Headquarters | Redwood City, CA |
| Industry | bio |
| Stage | series-b+ |
| Website | maplighttx.com |
MapLight Therapeutics develops small-molecule treatments for neuropsychiatric and neurological conditions including autism-related social symptoms and schizophrenia. Patients with serious psychiatric disorders are the eventual customer base. MapLight pursues circuit-targeted mechanisms in partnership with academic neuroscience labs.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-01 | series-d+ | $372.5M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $372.5M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $400.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | maplighttx.com, read 2026-05-26 |
| Description | self-reported | maplighttx.com, read 2026-05-26 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.